Neuroblastoma (NB) pathogenesis has been reported to be closely associated with
numerous genetic alterations. However, underlying DNA methylation patterns have not been …

Aim: To define the DNA methylation landscape of neuroblastoma and its clinicopathological
impact. Materials & methods: Microarray DNA methylation data were analyzed and …

The downregulation of specific genes through DNA hypermethylation is a major hallmark of
cancer, although the extent and genomic distribution of hypermethylation occurring within …

Neuroblastoma is a very heterogeneous tumor of childhood. The clinical spectra range from
very aggressive metastatic disease to spontaneous regression, even without therapy …

Background Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …

Neuroblastoma (NB), a developmental cancer, is often fatal, emphasizing the need to
understand its pathogenesis and identify new therapeutic targets. The heterogeneous …

Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore,
this study aims at establishing novel prognostic tumor DNA methylation biomarkers. In total …

The broad clinical spectrum of neuroblastoma ranges from spontaneous regression to rapid
progression despite intensive multimodal therapy. This diversity is not fully explained by …

CpG island hypermethylation has been recognized as an alternative mechanism for tumor
suppressor gene inactivation. In this study, we performed methylation-specific PCR (MSP) to …

Background Neuroblastoma is the most common malignancy in infancy, accounting for 15%
of childhood cancer deaths. Outcome for the high-risk disease remains poor. DNA …